Opening book details…
About this Medicine article
Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis by Peters, S; Ramalingam, S S; Paz-Ares, L; Bernabe Caro, R; Zurawski, B; Kim, S-W; Alexandru, A; Lupinacci, L; de la Mora Jimenez, E; Sakai, H; Albert, I; Vergnenegre, A; Reck, M; Borghaei, H; Brahmer, J R; O’Byrne, K J; Geese, W J; Bhagavatheeswaran, P; Nathan, F E; Hellmann, M D is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Peters, S; Ramalingam, S S; Paz-Ares, L; Bernabe Caro, R; Zurawski, B; Kim, S-W; Alexandru, A; Lupinacci, L; de la Mora Jimenez, E; Sakai, H; Albert, I; Vergnenegre, A; Reck, M; Borghaei, H; Brahmer, J R; O’Byrne, K J; Geese, W J; Bhagavatheeswaran, P; Nathan, F E; Hellmann, M D
- Publisher
- Oxford University Press; Elsevier BV (ISSN 0923-7534)
- Published
- 2019
- Field
- Medicine (Health Sciences)